An East Staffordshire experience of screening for atrial fibrillation with the AliveCor KardiaMobile
The use of novel technology to address problems in healthcare is one with great potential. In the case of atrial fibrillation, under diagnosis of the condition is a problem that is faced in the community. This can have devastating consequences for patients such as increased risk of strokes and mortality.
To tackle this, we trialled an initiative of rolling out AliveCor single lead ECG devices across 16 general practices in East Staffordshire. Through this initiative, 3772 patients not previously diagnosed with AF were screened and 49 new cases of AF have been diagnosed and suitable management initiated.
This article outlines key insights we have gained from our experience and highlights how single lead ECG devices were used to improve clinical outcomes for patients in East Staffordshire/ and at scale across Staffordshire general practices.
Savio M & Chambers R. Improving the utility and sustainability of novel health technology to improve clinical outcomes for patients: an East Staffordshire experience of screening for atrial fibrillation with the AliveCor KardiaMobile.